Chronic kidney disease: a practical guide (ACT-NAU)

Autores

  • Ana Corte-Real UCSP Barroselas, ULS do Alto Minho. Famalicão, Portugal | MTG Research and Development Lab. Porto, Portugal.
  • Andreia Nunes Internal Medicine Department, Hospital Garcia de Orta, EPE. Almada, Portugal.
  • Ana Isabel Rodrigues USF Cidade Jardim, ULS Viseu Dão-Lafões EPE. Viseu, Portugal.
  • Carolina Belino Centro Hospitalar Universitário Cova da Beira, ULS da Cova da Beira EPE. Covilhã, Portugal.
  • Cristina Outerelo Nephrology Department, ULS de Santa Maria EPE, Hospital Universitário de Santa Maria. Lisbon, Portugal.
  • Diogo Ramos USF São Teotónio, ULS Viseu Dão-Lafões EPE. Viseu, Portugal.
  • Gil Silva Hospital Dr. Nélio Mendonça, Serviço de Saúde da Região Autónoma da Madeira, EPE (SESARAM). Funchal, Portugal.
  • Gilberto Guimarães USF Felgaria Rubeans, ULS do Tâmega e Sousa EPE. Felgueiras, Portugal.
  • Henrique Sousa Nephrology Department, Hospital das Forças Armadas. Lisboa, Portugal.
  • Ines Aires Nephrology and Transplant Unit, Hospital Curry Cabral, ULS São José EPE. Lisbon, Portugal | NOVA Medical School, Universidade Nova de Lisboa. Lisboa, Portugal.
  • Ines Fortuna MTG Research and Development Lab. Porto, Portugal.
  • Ivan Luz Nephrology Department, ULS Médio Tejo EPE. Torres Novas, Portugal.
  • Joao Mario Goncalves USF Levante, ULS Algarve EPE. Vila Real de Santo António, Portugal.
  • Joao Pedro Nobre USF Rodrigues Miguéis, ULS de Santa Maria EPE, ACeS Lisboa Norte. Lisboa, Portugal.
  • Joaquim Calado Nephrology Department, Hospital Curry Cabral, ULS São José EPE. Lisbon, Portugal.
  • Jorge Malheiro Nephrology Department, Centro Hospitalar e Universitário de Santo António. Porto, Portugal | Instituto de Ciências Biomédicas de Abel Salazar Universidade do Porto (ICBAS/UP). Porto, Portugal.
  • Leila Cardoso Internal Medicine Department, Centro Hospitalar Universitário de São João, ULS São João. Porto, Portugal.
  • Leonor Luz-Duarte USF Caminho Novo, ULS Gaia Espinho EPE. Vila Nova de Gaia, Portugal | MTG Research and Development Lab. Porto, Portugal.
  • Luis Mendonca Nephrology Department, Centro Hospitalar Universitário de São João, ULS São João EPE. Porto, Portugal.
  • Luis Rodrigues Nephrology Department, Centro Hospitalar e Universitário de Coimbra, ULS Coimbra EPE. Coimbra, Portugal.
  • Manuel Amoedo Nephrology Department, Hospital Espírito Santo de Évora, ULS do Alentejo Central EPE. Évora, Portugal.
  • Miguel Bigotte Vieira Nephrology Department, Hospital Curry Cabral, ULS São José EPE. Lisbon, Portugal | NOVA Medical School, Universidade Nova de Lisboa. Lisboa, Portugal.
  • Paula Felgueiras Internal Medicine Department, ULS Alto Minho EPE. Viana do Castelo, Portugal.
  • Paulo Subtil Internal Medicine Department, Centro Hospitalar de Trás-os-Montes e Alto Douro, ULS Trás-os-Montes e Alto Douro EPE. Vila Real, Portugal.
  • Rita Lopes MTG Research and Development Lab. Porto, Portugal.
  • Sofia Homem Melo Nephrology Department, Hospital de Braga, ULS Braga EPE. Braga, Portugal.
  • Susana Heitor Internal Medicine Department, Integrated Diabetes Unit, Hospital Prof Doutor Fernando Fonseca, ULS de Amadora/Sintra EPE. Amadora, Portugal.
  • Vital Silva Domingues Internal Medicine Department, Centro Hospitalar e Universitário de Santo António, ULS de Santo António EPE. Porto, Portugal | Instituto de Ciências Biomédicas de Abel Salazar Universidade do Porto (ICBAS/UP). Porto, Portugal.
  • Zelia Lopes Internal Medicine Department, Centro Hospitalar do Tâmega e Sousa - Unidade Padre Américo, ULS do Tâmega e Sousa EPE. Penafiel, Portugal.

DOI:

https://doi.org/10.32385/ng2xa497

Palavras-chave:

Chronic kidney disease, Diagnosis, Disease management, Referral and consultation

Resumo

Chronic kidney disease (CKD) is a major public health problem that is associated with increased global morbidity and mortality and is a major risk factor for cardiovascular disease. The prevalence of CKD is increasing exponentially worldwide. Its prevalence in Portugal is 20.9% in CKD stages 1 to 5, and 9.8% for CKD stage ≥G3a/A1, so it is of utmost importance that this health problem be properly addressed in primary health care. The most common causes of CKD are hypertension and diabetes, and regular screening for CKD in these patients is recommended. Other contributing factors to CKD include acute kidney injury, obesity, smoking, infectious diseases, nephrotoxic drugs and, less frequently, contaminants in food or drinking water, heavy metals, industrial and agricultural chemicals, and high ambient temperatures. CKD is a major burden on health care systems with a propensity to increase due not only to the increasing prevalence of hypertension and diabetes but also to the aging population. This will result in greater demand on the healthcare system, greater consumption of resources, and greater economic expenditures on healthcare. Thus, it is of uttermost importance to develop awareness among physicians to prevent CKD and its risk factors, to properly screen for early diagnosis, and to correctly treat and refer to secondary health care facilities. To improve the care of patients with CKD and strengthen communication between healthcare providers, we present a document with the backbone guidelines for diagnosing CKD, its management according to its various etiologies, and referral criteria to hospital care.

Downloads

Os dados de download ainda não estão disponíveis.

Referências

Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, et al. The systemic nature of CKD. Nat Rev Nephrol. 2017;13(6):344-58.

GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-33.

Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160(8):1093-100.

Vinhas J, Aires I, Batista C, Branco P, Brandão J, Nogueira R, et al. RENA Study: cross-sectional study to evaluate CKD prevalence in Portugal. Nephron. 2020;144(10):479-87.

Santos-Araújo C, Mendonça L, Carvalho DS, Bernardo F, Pardal M, Couceiro J, et al. 20 years of real-world data to estimate chronic kidney disease prevalence and staging in an unselected population. Clin Kidney J. 2022;16:111-24.

Luyckx VA, Cherney DZ, Bello AK. Preventing CKD in developed countries. Kidney Int Rep. 2020;5(3):263-77.

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 11. Chronic kidney disease and risk management: standards of care in diabetes - 2023. Diabetes Care. 2023;46(Suppl 1):S191-202.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104.

Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80(12):1258-70.

Fraser SD, Roderick PJ, May CR, McIntyre N, McIntyre C, Fluck RJ, et al. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. BMC Nephrol. 2015;16:193.

Yacoub R, Habib H, Lahdo A, Al Ali R, Varjabedian L, Atalla G, et al. Association between smoking and chronic kidney disease: a case control study. BMC Public Health. 2010;10:731.

Lu JL, Molnar MZ, Naseer A, Mikkelsen MK, Kalantar-Zadeh K, Kovesdy CP. Association of age and BMI with kidney function and mortality: a cohort study. Lancet Diabetes Endocrinol. 2015;3(9):704-14.

Soderland P, Lovekar S, Weiner DE, Brooks DR, Kaufman JS. Chronic kidney disease associated with environmental toxins and exposures. Adv Chronic Kidney Dis. 2010;17(3):254-64.

Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-72.

Ekrikpo UE, Kengne AP, Bello AK, Effa EE, Noubiap JJ, Salako BL, et al. Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis. PLoS One. 2018;13(4):e0195443.

Ng JK, Li PK. Chronic kidney disease epidemic: how do we deal with it? Nephrology. 2018;23 Suppl 4:116-20.

Bello AK, Levin A, Manns BJ, Feehally J, Drueke T, Faruque L, et al. Effective CKD care in European countries: challenges and opportunities for health policy. Am J Kidney Dis. 2015;65(1):15-25.

Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol. 2017;13(7):393-409.

Evans M, Lewis RD, Morgan AR, Whyte MB, Hanif W, Bain SC, et al. A narrative review of chronic kidney disease in clinical practice: current challenges and future perspectives. Adv Ther. 2022;39(1):33-43.

KDIGO. CKD evaluation and management [homepage]. KDIGO; 2023 [cited 2023 Apr 6]. Available from: https://kdigo.org/guidelines/ckd-evaluation-and-management/

Ammirati AL. Chronic kidney disease. Rev Assoc Med Bras. 2020;66 Suppl 1:s03-9.

Gaitonde DY, Cook DL, Rivera IM. Chronic kidney disease: detection and evaluation. Am Fam Physician. 2017;96(12):776-83.

Ali I, Donne RL, Kalra PA. A validation study of the kidney failure risk equation in advanced chronic kidney disease according to disease aetiology with evaluation of discrimination, calibration and clinical utility. BMC Nephrol. 2021;22(1):194.

KDIGO. Early identification and intervention of chronic kidney disease speaker’s guide [Internet]. KDIGO; 2021 [cited 2023 Dec 20]. Available from: https://kdigo.org/wp-content/uploads/2019/01/KDIGO-CKD-Early-Intervention-Speakers-Guide.pdf

KDIGO. ISN-KDIGO early CKD screening booklet [Internet]. International Society of Nephrology; [s.d.] [cited 2023 Dec 20]. Available from: https://kdigo.org/wp-content/uploads/2019/01/ISN_KDIGO_EarlyScreeningBooklet_WEB.pdf

Moyer VA, U.S. Preventive Services Task Force. Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(8):567-70.

Chronic kidney disease: assessment and management [Internet]. London: National Institute for Health and Care Excellence (NICE); 2021 [cited 2023 Dec 20]. Available from: https://www.nice.org.uk/guidance/ng203/resources/chronic-kidney-disease-assessment-and-management-pdf-66143713055173

Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD, et al. Practical approach to detection and management of chronic kidney disease for the primary care clinician. Am J Med. 2016;129(2):153-62.e7.

Tuegel C, Bansal N. Heart failure in patients with kidney disease. Heart. 2017;103(23):1848-53.

Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-81.

Van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality: a collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341-52.

McMurray J, Parfrey P, Adamson JW, Aljama P, Berns JS, Bohlius J, et al. Kidney disease: improving global outcomes (KDIGO) anemia work group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279-335.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59.

James MT, Quan H, Tonelli M, Manns BJ, Faris P, Laupland KB, et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis. 2009;54(1):24-32.

Dalrymple LS, Katz R, Kestenbaum B, de Boer IH, Fried L, Sarnak MJ, et al. The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis. 2012;59(3):356-63.

Wu MY, Hsu YH, Su CL, Lin YF, Lin HW. Risk of herpes zoster in CKD: a matched-cohort study based on administrative data. Am J Kidney Dis. 2012;60(4):548-52.

Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis. 2006;13(3):199-204.

National Institute for Health and Care Excellence. Dapagliflozin for treating chronic kidney disease [homepage]. NICE; 2022 Mar 9 [cited 2023 Apr 7]. Available from: https://www.nice.org.uk/guidance/ta775

National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management [homepage]. NICE; 2021 Aug 21 [cited 2023 Apr 7]. Available from: https://www.nice.org.uk/guidance/ng203

Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303-9.

International Diabetes Federation. IDF diabetes atlas 2021 [homepage]. IDF; 2021 [cited 2023 Apr 22]. Available from: https://diabetesatlas.org/atlas/tenth-edition/

Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. 2016;316(6):602-10.

de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532-9.

de Boer IH, DCCT/EDIC Research Group. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):24-30.

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1-127.

Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017;390(10105):1888-917.

Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302-8.

Fox CS, Matsushita K, Woodward M, Bilo HJG, Chalmers J, Heerspink HJL, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662-73.

American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45 Suppl 1:S17-38.

de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-90.

Bach KE, Kelly JT, Palmer SC, Khalesi S, Strippoli GFM, Campbell KL. Healthy dietary patterns and incidence of CKD: a meta-analysis of cohort studies. Clin J Am Soc Nephrol. 2019;14(10):1441-9.

Joint WHO/FAO/UNU Expert Consultation. Protein and amino acid requirements in human nutrition. World Health Organ Tech Rep Ser. 2007;(935).

Murray DP, Young L, Waller J, Wright S, Colombo R, Baer S, et al. Is dietary protein intake predictive of 1-year mortality in dialysis patients? Am J Med Sci. 2018;356(3):234-43.

Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease: Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330(13):877-84.

Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med. 2014;371(7):624-34.

Whaley-Connell A, Sowers JR. Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. Kidney Int. 2017;92(2):313-23.

DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol. 2014;2(10):793-800.

DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365(25):2366-76.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.

Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419-30.

Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(6):431-7.

Agrawal L, Azad N, Bahn GD, Ge L, Reaven PD, Hayward RA, et al. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia. 2018;61(2):295-9.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-306.

Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-46.

The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-27.

Neuen BL, Young T, Heerspink HJ, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845-54.

American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S144-74.

Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol. 2020;15(12):1715-27.

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-29.

Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, et al. Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. J Am Soc Nephrol. 2022;33(1):225-37.

Subbiah AK, Chhabra YK, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia. 2016;8(2):56-61.

Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23 Suppl 2:1-87.

Vallianou NG, Mitesh S, Gkogkou A, Geladari E. Chronic kidney disease and cardiovascular disease: is there any relationship? Curr Cardiol Rev. 2019;15(1):55-63.

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305.

Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009 - Hypertension and kidney disease: a marriage that should be prevented. Clin J Am Soc Nephrol. 2009;4(3):517-9.

Anderson AH, Yang W, Townsend RR, Pan Q, Chertow GM, Kusek JW, et al. Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study. Ann Intern Med. 2015;162(4):258-65.

Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238-52.

Gansevoort RT. Too much nephrology? The CKD epidemic is real and concerning. A PRO view. Nephrol Dial Transplant. 2019;34(4):577-80.

Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. Drugs. 2019;79(4):365-79.

Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis. 2010;55(3):441-51.

Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339-52.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-248.

Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment (a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research). Circulation. 2008;117(25):e510-26.

Herrmann SM, Textor SC. Current concepts in the treatment of renovascular hypertension. Am J Hypertens. 2018;31(2):139-49.

Chrysochou C, Kalra PA. Epidemiology and natural history of atherosclerotic renovascular disease. Prog Cardiovasc Dis. 2009;52(3):184-95.

Noilhan C, Barigou M, Bieler L, Amar J, Chamontin B, Bouhanick B. Causes of secondary hypertension in the young population: a monocentric study. Ann Cardiol Angeiol. 2016;65(3):159-64.

Herrmann SM, Textor SC. Renovascular hypertension. Endocrinol Metab Clin North Am. 2019;48(4):765-78.

Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med. 2001;344(6):431-42.

Lao D, Parasher PS, Cho KC, Yeghiazarians Y. Atherosclerotic renal artery stenosis: diagnosis and treatment. Mayo Clin Proc. 2011;86(7):649-57.

Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13-8.

Bell EK, Gao L, Judd S, Glasser SP, McClellan W, Gutiérrez OM, et al. Blood pressure indexes and end-stage renal disease risk in adults with chronic kidney disease. Am J Hypertens. 2012;25(7):789-96.

Young JH, Klag MJ, Muntner P, Whyte JL, Pahor M, Coresh J. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol. 2002;13(11):2776-82.

Carpio EM, Ashworth M, Asgari E, Shaw C, Schartau P, Durbaba S, et al. Hypertension and cardiovascular risk factor management in a multi-ethnic cohort of adults with CKD: a cross sectional study in general practice. J Nephrol. 2022;35(3):901-10.

Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol. 2018;14(3):151-64.

Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, et al. Effects of intensive BP control in CKD. J Am Soc Nephrol. 2017;28(9):2812-23.

Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421-31.

Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11(5):532-46.

Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016;315(24):2673-82.

Beddhu S, Rocco MV, Toto R, Craven TE, Greene T, Bhatt U, et al. Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: a secondary analysis of a randomized trial. Ann Intern Med. 2017;167(6):375-83.

SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-16.

Peralta CA, McClure LA, Scherzer R, Odden MC, White CL, Shlipak M, et al. Effect of intensive versus usual blood pressure control on kidney function among individuals with prior lacunar stroke: a post hoc analysis of the secondary prevention of small subcortical strokes (SPS3) randomized trial. Circulation. 2016;133(6):584-91.

Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363(10):918-29.

Wright JT Jr, Whelton PK, Johnson KC, Snyder JK, Reboussin DM, Cushman WC, et al. SPRINT revisited: updated results and implications. Hypertension. 2021;78(6):1701-10.

Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1-87.

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20.

Kallioinen N, Hill A, Horswill MS, Ward HE, Watson MO. Sources of inaccuracy in the measurement of adult patients’ resting blood pressure in clinical settings: a systematic review. J Hypertens. 2017;35(3):421-41.

Stergiou GS, Kollias A, Destounis A, Tzamouranis D. Automated blood pressure measurement in atrial fibrillation: a systematic review and meta-analysis. J Hypertens. 2013;31(1):215-6.

Cohen DL, Huan Y, Townsend RR. Home blood pressure monitoring in CKD. Am J Kidney Dis. 2014;63(5):835-42.

Minutolo R, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, et al. Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study. Am J Kidney Dis. 2014;64(5):744-52.

Sun L, Yan B, Gao Y, Su D, Peng L, Jiao Y, et al. Relationship between blood pressure reverse dipping and type 2 diabetes in hypertensive patients. Sci Rep. 2016;6:25053.

McMahon EJ, Campbell KL, Bauer JD, Mudge DW, Kelly JT. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev. 2021;(6):CD010070.

Suckling RJ, He FJ, Macgregor GA. Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev. 2010;(12):CD006763.

Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink HJ, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ. 2011;343:d4366.

Flesher M, Woo P, Chiu A, Charlebois A, Warburton DE, Leslie B. Self-management and biomedical outcomes of a cooking, and exercise program for patients with chronic kidney disease. J Ren Nutr. 2011;21(2):188-95.

Heiwe S, Jacobson SH. Exercise training in adults with CKD: a systematic review and meta-analysis. Am J Kidney Dis. 2014;64(3):383-93.

Beddhu S, Wei G, Marcus RL, Chonchol M, Greene T. Light-intensity physical activities and mortality in the United States general population and CKD subpopulation. Clin J Am Soc Nephrol. 2015;10(7):1145-53.

Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(10):1565-74.

Morales E, Valero MA, León M, Hernández E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41(2):319-27.

Hull S, Dreyer G, Badrick E, Chesser A, Yaqoob MM. The relationship of ethnicity to the prevalence and management of hypertension and associated chronic kidney disease. BMC Nephrol. 2011;12:41.

Fraser SD, Roderick PJ, McIntyre NJ, Harris S, McIntyre CW, Fluck RJ, et al. Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care. BMC Fam Pract. 2013;14:88.

Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition (a patient-level meta-analysis). Ann Intern Med. 2003;139(4):244-52.

Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49(1):12-26.

Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366(9502):2026-33.

Solomon SD, Rice MM, A Jablonski K, Jose P, Domanski M, Sabatine M, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation. 2006;114(1):26-31.

Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134(8):629-36.

Clase CM, Barzilay J, Gao P, Smyth A, Schmieder RE, Tobe S, et al. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int. 2017;91(3):683-90.

Clase CM, Carrero JJ, Ellison DH, Grams ME, Hemmelgarn BR, Jardine MJ, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2020;97(1):42-61.

Zamboli P, De Nicola L, Minutolo R, Chiodini P, Crivaro M, Tassinario S, et al. Effect of furosemide on left ventricular mass in non-dialysis chronic kidney disease patients: a randomized controlled trial. Nephrol Dial Transplant. 2011;26(5):1575-83.

Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol. 2009;54(6):505-12.

Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884-94.

Currie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2016;17(1):127.

Dhaybi OA, Bakris G. Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017;26(1):50-5.

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019;50(5):333-44.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9.

Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28.

Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007;50(7):563-72.

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1-276.

Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2019;95(2):268-80.

Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177-83.

Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318(5):432-42.

Hebert LA, Birmingham DJ, Shidham G, Rovin B, Nagaraja HN, Yu CY. Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients. Nephron Clin Pract. 2009;113(3):c177-82.

Ix JH, Wassel CL, Stevens LA, Beck GJ, Froissart M, Navis G, et al. Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. Clin J Am Soc Nephrol. 2011;6(1):184-91.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.

Pottel H, Mottaghy FM, Zaman Z, Martens F. On the relationship between glomerular filtration rate and serum creatinine in children. Pediatr Nephrol. 2010;25(5):927-34.

Branten AJ, Vervoort G, Wetzels JF. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant. 2005;20(4):707-11.

Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu Rev Med. 1988;39:465-90.

Zhai JL, Ge N, Zhen Y, Zhao Q, Liu C. Corticosteroids significantly increase serum cystatin C concentration without affecting renal function in symptomatic heart failure. Clin Lab. 2016;62(1-2):203-7.

Goyal A, Daneshpajouhnejad P, Hashmi MF, Bashir K. Acute kidney injury. Treasure Island: StatPearls Publishing; 2023.

Geetha D, Seo P, Ellis C, Kuperman M, Levine SM. Persistent or new onset microscopic hematuria in patients with small vessel vasculitis in remission: findings on renal biopsy. J Rheumatol. 2012;39(7):1413-7.

Sevillano AM, Gutiérrez E, Yuste C, Cavero T, Mérida E, Rodríguez P, et al. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol. 2017;28(10):3089-99.

Coppo R, Fervenza FC. Persistent microscopic hematuria as a risk factor for progression of IgA nephropathy: new floodlight on a nearly forgotten biomarker. J Am Soc Nephrol. 2017;28(10):2831-4.

Joseph JJ, Echouffo-Tcheugui JB, Kalyani RR, Yeh HC, Bertoni AG, Effoe VS, et al. Aldosterone, renin, cardiovascular events, and all-cause mortality among African Americans: the Jackson Heart Study. JACC Heart Fail. 2017;5(9):642-51.

Petrykiv SI, Laverman GD, Persson F, Vogt L, Rossing P, de Borst MH, et al. Pooled analysis of multiple crossover trials to optimize individual therapy response to renin-angiotensin-aldosterone system intervention. Clin J Am Soc Nephrol. 2017;12(11):1804-13.

Antlanger M, Bernhofer S, Kovarik JJ, Kopecky C, Kaltenecker CC, Domenig O, et al. Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease. Ann Med. 2017;49(6):525-33.

Rajasekeran H, Reich HN, Hladunewich MA, Cattran D, Lovshin JA, Lytvyn Y, et al. Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. Am J Physiol Renal Physiol. 2018;314(3):F412-22.

Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018;14(1):57-70.

Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41-52.

Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L. Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev. 2013;(12):CD005425.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-22.

Pincus KJ, Hynicka LM. Prophylaxis of thromboembolic events in patients with nephrotic syndrome. Ann Pharmacother. 2013;47(5):725-34.

Sexton DJ, Freitas DG, Little MA, McHugh T, Magee C, Conlon PJ, et al. Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome. Kidney Int Rep. 2018;3(4):784-93.

National Institute of Diabetes and Digestive and Kidney Diseases. Modification of diet in renal disease (MDRD) [homepage]. NIDDK Central Repository; 2023. Available from: https://repository.niddk.nih.gov/studies/mdrd/

Oliverio AL, Zee J, Mariani LH, Reynolds ML, O’Shaughnessy M, Hendren EM, et al. Renal complications in pregnancy preceding glomerulonephropathy diagnosis. Kidney Int Rep. 2019;4(1):159-62.

Piccoli GB, Attini R, Cabiddu G, Kooij I, Fassio F, Gerbino M, et al. Maternal-foetal outcomes in pregnant women with glomerulonephritides: are all glomerulonephritides alike in pregnancy? J Autoimmun. 2017;79:91-8.

Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med. 2015;163(3):153-63.

Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010;5(11):2060-8.

Davison JM, Katz AI, Lindheimer MD. Kidney disease and pregnancy: obstetric outcome and long-term renal prognosis. Clin Perinatol. 1985;12(3):497-519.

Jungers P, Forget D, Henry-Amar M, Albouze G, Fournier P, Vischer U, et al. Chronic kidney disease and pregnancy. Adv Nephrol Necker Hosp. 1986;15:103-41.

Lindheimer MD, Katz AI. Gestation in women with kidney disease: prognosis and management. Bailliere Clin Obstet Gynaecol. 1994;8(2):387-404.

Park S, Lee SM, Park JS, Hong JS, Chin HJ, Na KY, et al. Midterm eGFR and adverse pregnancy outcomes: the clinical significance of gestational hyperfiltration. Clin J Am Soc Nephrol. 2017;12(7):1048-56.

Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, et al.; ERA-EDTA Registry; EuroCYST Consortium; WGIKD. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2014;29 Suppl 4:iv15-25.

Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis. 2016;67(5):792-810.

Lanktree MB, Haghighi A, Guiard E, Iliuta IA, Song X, Harris PC, et al. Prevalence estimates of polycystic kidney and liver disease by population sequencing. J Am Soc Nephrol. 2018;29(10):2593-600.

Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. 2017;32(8):1356-63.

Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019;393(10174):919-35.

Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2006;1(1):148-57.

Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2015 Jul;88(1):17-27.

Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287-301.

Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7(3):479-86.

Cornec-Le Gall E, Torres VE, Harris PC. Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol. 2018;29(1):13-23.

Hateboer N, Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, Millan JL, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. Lancet. 1999;353(9147):103-7.

Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2006;17(11):3013-9.

Pei Y, Watnick T. Diagnosis and screening of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010;17(2):140-52.

Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205-12.

Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, et al. Mutations in GANAB, encoding the glucosidase IIα subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet. 2016;98(6):1193-207.

Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, et al. Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. Am J Hum Genet. 2018;102(5):832-44.

Senum SR, Li YS, Benson KA, Joli G, Olinger E, Lavu S, et al. Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. Am J Hum Genet. 2022;109(1):136-56.

Ali H, Al-Mulla F, Hussain N, Naim M, Asbeutah AM, AlSahow A, et al. PKD1 Duplicated regions limit clinical utility of whole exome sequencing for genetic diagnosis of autosomal dominant polycystic kidney disease. Sci Rep. 2019;9(1):4141.

Pei Y, Paterson AD, Wang KR, He N, Hefferton D, Watnick T, et al. Bilineal disease and trans-heterozygotes in autosomal dominant polycystic kidney disease. Am J Hum Genet. 2001;68(2):355-63.

Paul BM, Consugar MB, Ryan Lee M, Sundsbak JL, Heyer CM, Rossetti S, et al. Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families. Kidney Int. 2014;85(2):383-92.

Kanaan N, Devuyst O, Pirson Y. Renal transplantation in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2014;10(8):455-65.

EAF co-chairs, Harris T, Sandford R, EAF members, Roundtable participants. European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants. Nephrol Dial Transplant. 2018;33(4):563-73.

Ars E, Bernis C, Fraga G, Furlano M, Martínez V, Martins J, et al. Documento de consenso de poliquistosis renal autosómica dominante del grupo de trabajo de enfermedades hereditarias de la Sociedad Española de Nefrología: revisión 2020 [Consensus document on autosomal dominant polycystic kindey disease from the Spanish Working Group on Inherited Kindey Diseases: review 2020]. Nefrología. 2022;42:367-89. Spanish

Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJ, Torres VE. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4(1):50.

Sanon Aigbogun M, Oberdhan D, Doane MJ, Rooney J, Inyart BC, Pao CS, et al. Disconnect in assessments of autosomal dominant polycystic kidney disease burden between patients and physicians: a survey study. Int J Nephrol Renovasc Dis. 2021;14:105-15.

Orskov B, Sørensen VR, Feldt-Rasmussen B, Strandgaard S. Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Nephrol Dial Transplant. 2012;27(4):1607-13.

Wetmore JB, Calvet JP, Yu AS, Lynch CF, Wang CJ, Kasiske BL, et al. Polycystic kidney disease and cancer after renal transplantation. J Am Soc Nephrol. 2014;25(10):2335-41.

Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, et al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis. 2014;63(2):214-26.

Ecder T. Cardiovascular complications in autosomal dominant polycystic kidney disease. Curr Hypertens Rev. 2013;9(1):2-11.

Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2255-66.

Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2267-76.

Sallée M, Rafat C, Zahar JR, Paulmier B, Grünfeld JP, Knebelmann B, et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2009;4(7):1183-9.

Jouret F, Lhommel R, Devuyst O, Annet L, Pirson Y, Hassoun Z, et al. Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities. Nephrol Dial Transplant. 2012;27(10):3746-51.

Lantinga MA, Drenth JPH, Gevers TJG. Diagnostic criteria in renal and hepatic cyst infection. Nephrol Dial Transplant. 2015;30(5):744-51.

Kanaan N, Goffin E, Pirson Y, Devuyst O, Hassoun Z. Carbohydrate antigen 19-9 as a diagnostic marker for hepatic cyst infection in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2010;55(5):916-22.

Fukasawa H, Kaneko M, Niwa H, Yasuda H, Kumagai H, Furuya R. Carbohydrate antigen 19-9 is significantly elevated in autosomal dominant polycystic kidney disease. Nephrology. 2018;23(3):210-6.

Alam A, Perrone RD. Managing cyst infections in ADPKD: an old problem looking for new answers. Clin J Am Soc Nephrol. 2009;4(7):1154-5.

Peces R, Aguilar A, Vega C, Cuesta E, Peces C, Selgas R. Medical therapy with tranexamic acid in autosomal dominant polycystic kidney disease patients with severe haematuria. Nefrologia. 2012;32(2):160-5.

Grampsas SA, Chandhoke PS, Fan J, Glass MA, Townsend R, Johnson AM, et al. Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;36(1):53-7.

Torres VE, Wilson DM, Hattery RR, Segura JW. Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993;22(4):513-9.

Qu M, Ramirez-Giraldo JC, Leng S, Williams JC, Vrtiska TJ, Lieske JC, et al. Dual-energy dual-source CT with additional spectral filtration can improve the differentiation of non-uric acid renal stones: an ex vivo phantom study. AJR Am J Roentgenol. 2011;196(6):1279-87.

Umbreit EC, Childs MA, Patterson DE, Torres VE, LeRoy AJ, Gettman MT. Percutaneous nephrolithotomy for large or multiple upper tract calculi and autosomal dominant polycystic kidney disease. J Urol. 2010;183(1):183-7.

Mufti UB, Nalagatla SK. Nephrolithiasis in autosomal dominant polycystic kidney disease. J Endourol. 2010;24(10):1557-61.

Yili L, Yongzhi L, Ning L, Dongwei X, Chunlai L, Suomin L, et al. Flexible ureteroscopy and holmium laser lithotripsy for treatment of upper urinary tract calculi in patients with autosomal dominant polycystic kidney disease. Urol Res. 2012;40(1):87-91.

Bajwa ZH, Gupta S, Warfield CA, Steinman TI. Pain management in polycystic kidney disease. Kidney Int. 2001;60(5):1631-44.

Hogan MC, Norby SM. Evaluation and management of pain in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010;17(3):e1-16.

Grantham JJ. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359(14):1477-85.

Lanktree MB, Chapman AB. New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol. 2017;13(12):750-68.

Savige J, Tunnicliffe DJ, Rangan GK. KHA-CARI autosomal dominant kidney disease guideline: management of chronic pain. Semin Nephrol. 2015;35(6):607-11.e3.

Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, et al. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol. 2015 Jan;13(1):155-64.e6.

Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006;1(1):64-9.

Jouret F, Lhommel R, Beguin C, Devuyst O, Pirson Y, Hassoun Z, et al. Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6(7):1644-50.

Masoumi A, Reed-Gitomer B, Kelleher C, Bekheirnia MR, Schrier RW. Developments in the management of autosomal dominant polycystic kidney disease. Ther Clin Risk Manag. 2008;4(2):393-407.

Chebib FT, Jung Y, Heyer CM, Irazabal MV, Hogan MC, Harris PC, et al. Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2016;31(6):952-60.

Sherstha R, McKinley C, Russ P, Scherzinger A, Bronner T, Showalter R, et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology. 1997;26(5):1282-6.

Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol. 2013;10(2):101-8.

Griffiths J, Mills MT, Ong AC. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis. BMJ Open. 2020;10(1):e032620.

Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE. Medical and surgical treatment options for polycystic liver disease. Hepatology. 2010;52(6):2223-30.

Hogan MC, Masyuk TV, Page L, Holmes DR 3rd, Li X, Bergstralh EJ, et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant. 2012;27(9):3532-9.

Neijenhuis MK, Gevers TJ, Nevens F, Hogan MC, Torres VE, Kievit W, et al. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials. Aliment Pharmacol Ther. 2015;42(5):591-8.

Irazabal MV, Huston J 3rd, Kubly V, Rossetti S, Sundsbak JL, Hogan MC, et al. Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6(6):1274-85.

Xu HW, Yu SQ, Mei CL, Li MH. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. Stroke. 2011;42(1):204-6.

Pirson Y, Chauveau D, Torres V. Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2002;13(1):269-76.

Flahault A, Joly D. Screening for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2019;14(8):1242-4.

Nurmonen HJ, Huttunen T, Huttunen J, Kurki MI, Helin K, Koivisto T, et al. Polycystic kidney disease among 4,436 intracranial aneurysm patients from a defined population. Neurology. 2017;89(18):1852-9.

Yoo DJ, Agodoa L, Yuan CM, Abbott KC, Nee R. Risk of intracranial hemorrhage associated with autosomal dominant polycystic kidney disease in patients with end stage renal disease. BMC Nephrol. 2014;15:39.

Ring T, Spiegelhalter D. Risk of intracranial aneurysm bleeding in autosomal-dominant polycystic kidney disease. Kidney Int. 2007;72(11):1400-2.

Zhou Z, Xu Y, Delcourt C, Shan J, Li Q, Xu J, et al. Is regular screening for intracranial aneurysm necessary in patients with autosomal dominant polycystic kidney disease? A systematic review and meta-analysis. Cerebrovasc Dis. 2017;44(1-2):75-82.

Cheungpasitporn W, Thongprayoon C, Ungprasert P, Wijarnpreecha K, Kaewput W, Leeaphorn N, et al. Subarachnoid hemorrhage in hospitalized renal transplant recipients with autosomal dominant polycystic kidney disease: a nationwide analysis. J Clin Med Res. 2019;8(4):524.

Naggara O, Darsaut T, Trystram D, Tselikas L, Raymond J. Unruptured intracranial aneurysms: why we must not perpetuate the impasse for another 25 years. Lancet Neurol. 2014;13(6):537-8.

Williams LN, Brown RD Jr. Management of unruptured intracranial aneurysms. Neurol Clin Pract. 2013;3(2):99-108.

Budhram B, Akbari A, Brown P, Biyani M, Knoll G, Zimmerman D, et al. End-stage kidney disease in patients with autosomal dominant polycystic kidney disease: a 12-year study based on the Canadian Organ Replacement Registry. Can J Kidney Health Dis. 2018;5:2054358118778568.

Jung Y, Irazabal MV, Chebib FT, Harris PC, Dean PG, Prieto M, et al. Volume regression of native polycystic kidneys after renal transplantation. Nephrol Dial Transplant. 2016;31(1):73-9.

Kirkman MA, van Dellen D, Mehra S, Campbell BA, Tavakoli A, Pararajasingam R, et al. Native nephrectomy for autosomal dominant polycystic kidney disease: before or after kidney transplantation? BJU Int. 2011;108(4):590-4.

Patel P, Horsfield C, Compton F, Taylor J, Koffman G, Olsburgh J. Native nephrectomy in transplant patients with autosomal dominant polycystic kidney disease. Ann R Coll Surg Engl. 2011;93(5):391-5.

Chapman AB, Johnson AM, Gabow PA. Pregnancy outcome and its relationship to progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994;5(5):1178-85.

Harper JC, Wilton L, Traeger-Synodinos J, Goossens V, Moutou C, SenGupta SB, et al. The ESHRE PGD Consortium: 10 years of data collection. Hum Reprod Update. 2012;18(3):234-47.

Rechitsky S, Verlinsky O, Kuliev A. PGD for cystic fibrosis patients and couples at risk of an additional genetic disorder combined with 24-chromosome aneuploidy testing. Reprod Biomed Online. 2013;26(5):420-30.

Gigarel N, Frydman N, Burlet P, Kerbrat V, Tachdjian G, Fanchin R, et al. Preimplantation genetic diagnosis for autosomal recessive polycystic kidney disease. Reprod Biomed Online. 2008;16(1):152-8.

Malek J, Daar J. The case for a parental duty to use preimplantation genetic diagnosis for medical benefit. Am J Bioeth. 2012;12(4):3-11.

Melo-Martín I. A parental duty to use PGD: more than we bargained for? Am J Bioeth. 2012;12(4):14-5.

Goldsammler M, Jotkowitz A. The ethics of PGD: what about the physician? Am J Bioeth. 2012;12(4):28-9.

Mei CL, Xue C, Yu SQ, Dai B, Chen JH, Li Y, et al. Executive summary: clinical practice guideline for autosomal dominant polycystic kidney disease in China. Kidney Dis (Basel). 2020;6(3):144-9.

Grantham JJ, Torres VE. The importance of total kidney volume in evaluating progression of polycystic kidney disease. Nat Rev Nephrol. 2016;12(11):667-77.

European Medicines Agency. Jinarc, INN-tolvaptan: product information [Internet]. EMA; [s.d.] [cited 2023 Dec 20]. Available from: https://www.ema.europa.eu/en/documents/product-information/jinarc-epar-product-information_en.pdf

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407-18.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930-42.

Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10(4):363-4.

Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19(1):102-8.

Müller RU, Messchendorp AL, Birn H, Capasso G, Cornec-Le Gall E, Devuyst O, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrol Dial Transplant. 2022;37(5):825-39.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial. Nephrol Dial Transplant. 2018;33(3):477-89.

Perrone RD, Coons SJ, Cavanaugh K, Finkelstein F, Meyer KB. Patient-reported outcomes in clinical trials of CKD-related therapies: report of a symposium sponsored by the national kidney foundation and the U.S. Food and Drug Administration. Am J Kidney Dis. 2013;62(6):1046-57.

Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160-72.

Mayo Foundation for Medical Education and Research. ADPKD Classification [Internet]. MFMER; [s.d.] [cited 2023 Jun 24]. Available from: https://www.mayo.edu/research/documents/pkd-center-adpkd-classification/doc-20094754

Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29(10):2458-70.

Oliveira I, Jacinto R, Pestana S, Nolasco F, Calado J, Lopes SS, et al. Zebrafish model as a screen to prevent cyst inflation in autosomal dominant polycystic kidney disease. Int J Mol Sci. 2021;22(16):9013.

Cornec-Le Gall E, Audrézet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24(6):1006-13.

Lavu S, Vaughan LE, Senum SR, Kline TL, Chapman AB, Perrone RD, et al. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight. 2020;5(15):e138724.

Cornec-Le Gall E, Audrézet MP, Rousseau A, Hourmant M, Renaudineau E, Charasse C, et al. The PROPKD Score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(3):942-51.

Bais T, Gansevoort RT, Meijer E. Drugs in clinical development to treat autosomal dominant polycystic kidney disease. Drugs. 2022;82(10):1095-115.

Nesbitt H. American Society of Nephrology [homepage]. ASN; 2021 [cited 2023 Jun 24]. Available from: https://www.asn-online.org/education/kidneyweek/2021/program-abstract.aspx?controlId=3624964

Downloads

Publicado

14-02-2024

Edição

Secção

Formação

Como Citar

Chronic kidney disease: a practical guide (ACT-NAU). (2024). Revista Portuguesa De Medicina Geral E Familiar, 40. https://doi.org/10.32385/ng2xa497

Artigos Similares

1-10 de 648

Também poderá iniciar uma pesquisa avançada de similaridade para este artigo.